# KPV Legal Status, FDA 503A Category, and Compounding Access | KPV peptide > KPV legal status and the FDA 503A framework: the KPV peptide is a research compound, not FDA-approved, and is named on the FDA PCAC agenda for July 23-24, 2026 as a substance being considered for the 503A bulks list. Where access actually stands: a research peptide, not an approved drug, with its compounding eligibility under active FDA review — and individually named on a scheduled 2026 advisory-committee agenda. The facts, present-tense, cited to the FDA. ## In plain English Here is the KPV legal status in a sentence: it is a research peptide, not an FDA-approved medicine, and you cannot buy it as a drug or a supplement. The forward-leaning part — and it is genuinely live — is that the FDA has scheduled KPV for discussion. It is named on the public agenda of an FDA advisory-committee meeting set for July 23-24, 2026, where experts will consider whether it belongs on a list of substances that compounding pharmacies are allowed to use. That is a scheduled conversation, not a decision, not a reclassification, and not a change in today's status. Below, what that framework means and how legal compounded access works in general. ## The current fact: a research peptide under FDA evaluation KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH) — is a research peptide and is not an FDA-approved drug for any indication [1]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list; substances not yet on that list are evaluated by the FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) — an external expert panel that advises the agency [1][3]. KPV is one of the bulk drug substances the FDA has scheduled for PCAC evaluation [3]. That is the precise present-tense status: being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. This site does not assign KPV a numbered 503A category, because the FDA's current record places KPV on a scheduled-for-discussion agenda rather than in a published category [3]. ## Active FDA review: KPV on the July 2026 PCAC agenda The momentum is real, and it is anchored to a specific, citable fact. KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — evaluated in both its free-base and acetate forms [3]. The same agenda also lists BPC-157, TB-500, and MOTs-C [3]. Access for this class of peptide is, in other words, under active FDA review and may expand in 2026. That is where the momentum stops and the caution begins. A scheduled PCAC discussion is an evaluation step, not an outcome: it is not a listing decision, not a reclassification, and not a change in KPV's current status [3]. PCAC is advisory — the committee's discussion informs the FDA, but inclusion on a final bulks list is decided by FDA rulemaking, and no outcome of the July 2026 meeting can be assumed, stated, or dated [3]. This page reports a scheduled evaluation, nothing more. ## The 503A and 503B framework, in brief Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding [1]. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [1]. The constraint that matters for a research peptide is the ingredient rule: a compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [1]. Substances that don't meet one of those conditions must be nominated and evaluated — which is exactly the process KPV is currently in [1][3]. Separately, the FDA's interim policy historically sorted nominated substances into categories, and on January 7, 2025 the FDA finalized a revised policy under which it no longer places newly nominated substances into those numbered categories [1]. None of that changes the core point for KPV: it is not an FDA-approved drug, and its compounding eligibility is under evaluation [1][3]. ## How legally compounded peptide access works For peptides of this class, legal compounded access — where a substance is eligible at all — runs through a defined pathway [1]. A patient is first evaluated by an appropriately licensed prescriber, in person or through a compliant telehealth encounter, who determines whether a compounded preparation is clinically appropriate [1]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription [1]. That prescription is then dispensed by a state-licensed 503A compounding pharmacy or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [1]. Telehealth functions here only as a front-end channel for the prescriber-evaluation step — a route to a licensed consultation and a valid prescription [1]. It does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation [1]. And the ingredient-eligibility caveat governs the whole pathway: a substance the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands, regardless of the prescription channel [1]. Because KPV's eligibility is under evaluation rather than settled, that caveat is the operative one here [1][3]. This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance. ## Common questions about KPV legal status and access Three questions come up repeatedly about where KPV stands. The short answers are below; each is drawn from the FDA framework described above. --- A two-sided reading of the KPV tripeptide record — the PepT1 gut-uptake and NF-kB findings logged to source on one plane, the research-only FDA status held plainly on the other; no clinic behind the seam and nothing here dispensed or sold.